The contraceptive efficacy, cycle control, safety, and subject acceptance of the new
contraceptive (OC) preparations containing gestodene (GTD) plus ethinyl estradiol (EE) are …

Objective To assess the contraceptive efficacy, cycle control and acceptability of two
monophasic oral contraceptives containing either 30 µg ethinylestradiol plus 150 µg …

Objectives: This multicenter, open-label study was conducted to compare the cycle control,
efficacy and safety of a 24-day regimen of a new ultra-low-dose oral contraceptive …

This long-term, open-label, multicenter study investigated the clinical efficacy and tolerability
of a monophasic oral contraceptive containing 20 μg ethinylestradiol and 75 μ ggestodene …

The efficacy and acceptability of two third generation oral contraceptives in Thai women
were evaluated in a prospective, open, group-comparative, randomized, multicenter trial of …

A triphasic oral contraceptive containing ethinyl estradiol and gestodene was used by 1933
women for up to 36 cycles in order to evaluate contraceptive efficacy, general tolerance and …

The monophasic low-dose contraceptive containing 30 μg of ethinyl estradiol and 75 μg of
gestodene has been tested in numerous clinical studies to determine contraceptive …

Two monophasic oral contraceptives containing gestodene (GTD, 15 μg) and
ethinylestradiol (EE, 30 μg) or norgestimate (NGS, 250 μg) and EE (35 μg) were compared …

The purpose of this study was to compare cycle control, efficacy and side effects of an oral
contraceptive containing 20 μg ethinylestradiol and 75 μg gestodene, with a reference …

Objective To compare two oral contraceptive pills, both containing 150 μg desogestrel, but
with either 20 μg (Mercilon®) or 30 μg (Marvelon®/Desolett®) ethinyl oestradiol (EE) …